Skip to content
OpenCapital
Get started

Corcept Therapeutics CORT Available-for-Sale Securities (Non-Current)

Available-for-Sale Securities (Non-Current) at other companies

Exelixis logo
ExelixisEXEL
——
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
——

Other financials

Income statement

See full
Revenue$164.9M+4.9%
Gross profit$162.0M+4.7%
Operating income-$49.6M-1,552%
Net income-$31.8M-255%
EPS (diluted)-$0.30-276%

Balance sheet

See full
Cash & equivalents$110.0M+21.1%
Total debt$9.6M+41.0%
Total equity$638.0M-6.6%
Total assets$814.9M-3.7%

Cash flow

See full
Operating cash flow-$16.8M-452%
CapEx$201.0K+93.3%
Free cash flow-$17.0M-464%

Valuation

See full
Market cap$8.58B-64.4%
Enterprise value$8.48B-65.0%
P/E181.2×+1.3×
P/S11.2×-24.0×

Profitability

See full
Gross margin98.3%-0.2pp
Operating margin-1.1%-17.2pp
Net margin6.2%-13.4pp
FCF margin15.6%-10.2pp

Returns & leverage

See full
Return on equity7.2%-14.6pp
Debt / equity0×0.0×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesNoncurrent.

The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corcept Therapeutics's available-for-sale securities (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corcept Therapeutics's available-for-sale securities (non-current)?
Corcept Therapeutics (CORT) reported available-for-sale securities (non-current) of $177.26M in Q1 2026.
How has Corcept Therapeutics's available-for-sale securities (non-current) changed year-over-year?
Corcept Therapeutics's available-for-sale securities (non-current) decreased by 28.5% year-over-year, from $248.04M to $177.26M.
What is the long-term trend for Corcept Therapeutics's available-for-sale securities (non-current)?
Over 5 years (2020 to 2025), Corcept Therapeutics's available-for-sale securities (non-current) has grown at a 34.7% compound annual growth rate (CAGR), from $36.2M to $160.27M.